Physician profile

Brian Howard

Advanced Heart Failure and Transplant Cardiology · Marietta, GA

NPI 1982832267

$98,702.84

in general payments reported to CMS, 2019-2025

36 companies · $12K in 2025

The $12K reported for 2025 was more than what 79% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Honoraria$36,150.00
Consulting Fee$29,389.00
Food and Beverage$9,291.21
Travel and Lodging$6,159.97
Education$25.70

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Cvrx, INC. $42,880.85 2019-2025 Barostim Neo System
Abiomed $35,581.01 2023-2024 Impella
Abbott Laboratories $9,414.86 2019-2025 Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems
Impulse Dynamics (USA) INC. $4,343.55 2022-2024 Optimizer, Optimizer
Novartis Pharmaceuticals Corporation $1,323.85 2019-2025
Daxor Corporation $765.64 2023-2024 Bva-100
Irras USA, INC. $682.91 2024
Medtronic, INC. $498.57 2023-2024 Pipeline, Symplicity G3, Cobalt Dr Mri Surescan
Astrazeneca Pharmaceuticals LP $402.70 2019-2025 Farxiga, Wainua
Medtronic Vascular, INC. $375.63 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $308.47 2019-2025 Jardiance
Boston Scientific Corporation $229.03 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $226.62 2022-2025 Lifevest
Inari Medical, INC. $195.80 2021
Pfizer INC. $185.05 2019-2025
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $154.32 2021-2025 Verquvo
Procyrion, INC. $136.28 2024
Bayer Healthcare Pharmaceuticals INC. $131.51 2024-2025
Asahi Intecc USA, INC. $125.95 2024 Peripheral Vascular
Novo Nordisk INC $108.66 2024-2025 Ozempic, Rybelsus, Wegovy
Scpharmaceuticals INC. $107.32 2023-2025
Daiichi Sankyo INC. $63.05 2019-2023 Injectafer
Teleflex LLC $59.76 2025
E.R. Squibb & Sons, L.L.C. $57.18 2019-2025 Camzyos
Lexicon Pharmaceuticals, INC. $50.68 2023-2024 Inpefa
Kestra Medical Technology Services, INC. $44.01 2023-2024 Assure Wcd
W. L. Gore & Associates, INC. $36.50 2021
Amgen INC. $35.95 2019
Janssen Pharmaceuticals, INC $31.13 2019-2020
Bridgebio Pharma, INC. $23.67 2025 Attruby
Actelion Pharmaceuticals US, INC. $23.45 2019
Cardiac Dimensions, INC. $23.13 2024
Amarin Pharma, INC. $20.18 2019
Sanofi-Aventis U.S. LLC $20.01 2019
United Therapeutics Corporation $18.97 2019
Vifor Pharma, INC. $16.59 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian Howard

$98,702.84

in general payments reported 2019-2025

Years
2019-2025
Top company
Cvrx, INC.
Context
The $12K reported for 2025 was more than what 79% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).

https://glasscript.com/doctor/1384812/brian-howard

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.